J Korean Med Sci.  2012 Nov;27(11):1405-1410. 10.3346/jkms.2012.27.11.1405.

Inhalation Therapy of Calcitonin Relieves Osteoarthritis of the Knee

• Armagan O
• Serin DK
• Calisir C
• Dokumacioglu A
• Ozgen M
• Oner S
• Alatas O

• KMID: 2157954
• DOI: http://doi.org/10.3346/jkms.2012.27.11.1405

Abstract

This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1beta, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20) received a home exercise program for 6 months. Compared with baseline,while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.

Keyword

Nasal Salmon Calcitonin; Knee Osteoarthritis; Exercise

MeSH Terms

Aged
Bone Density Conservation Agents/*therapeutic use
Calcitonin/*therapeutic use
Collagen Type II/urine
Exercise Therapy
Female
Humans
Interleukin-1beta/blood
Magnetic Resonance Imaging
Matrix Metalloproteinase 3/blood
Middle Aged
Nitric Oxide/blood
Osteoarthritis, Knee/*drug therapy/radiography
Peptide Fragments/urine
Respiratory Therapy
Severity of Illness Index
Treatment Outcome
Walking
Bone Density Conservation Agents
Collagen Type II
Interleukin-1beta
Peptide Fragments
Nitric Oxide
Calcitonin
Matrix Metalloproteinase 3

Reference

1. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010. 6:625–635.

2. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002. 39:237–246.

3. Meulenbelt I, Kloppenburg M, Kroon HM, Houwing-Duistermaat JJ, Garnero P, Hellio Le Graverand MP, Degroot J, Slagboom PE. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis. 2006. 65:360–365.

4. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004. 50:1193–1206.

5. Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, Qvist P, Christiansen C. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthritis Cartilage. 2006. 14:617–624.

6. Manicourt DH, Altman RD, Williams JM, Devogelaer JP, Druetz-Van Egeren A, Lenz ME, Pietryla D, Thonar EJ. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum. 1999. 42:1159–1167.

7. Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, Qvist P, Tankó LB, Bagger YZ, Christiansen C, Karsdal MA. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage. 2006. 14:759–768.

8. Sondergaard BC, Oestergaard S, Christiansen C, Tankó LB, Karsdal MA. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum. 2007. 56:2674–2678.

9. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006. 54:3205–3211.

10. Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG. Pain Relief From Nasal Salmon Calcitonin İn Osteoporotic Vertebral Crush Fractures. Acta Orthop Scand Suppl. 1997. 275:112–114.

11. Petrella RJ, Bartha C. Home based exercise therapy for older patients with knee osteoarthritis: a randomized clinical trial. J Rheumatol. 2000. 27:2215–2221.

12. Evcik D, Sonel B. Effectiveness of a home-based exercise therapy and walking program on osteoarthritis of the knee. Rheumatol Int. 2002. 22:103–106.

13. Bredella MA, Tirman PF, Peterfy CG, Zarlingo M, Feller JF, Bost FW, Belzer JP, Wischer TK, Genant HK. Accuracy of T2-weighted fast spin-echo MR imaging with fat saturation in detecting cartilage defects in the knee: comparison with arthroscopy in 130 patients. AJR Am J Roentgenol. 1999. 172:1073–1080.

14. van Baar ME, Dekker J, Lemmens JA, Oostendorp RA, Bijlsma JW. Pain and disability in patients with osteoarthritis of hip or knee: the relationship with articular, kinesiological and psychological characteristics. J Rheumatol. 1998. 25:125–133.

15. Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol. 2007. 26:44–49.

16. Takayama B, Kikuchi S, Konno S, Sekiguchi M. An immunohistochemical study of the antinociceptive effect of calcitonin in ovariectomized rats. BMC Musculoskelet Disord. 2008. 9:164.

17. Ito A, Kumamoto E, Takeda M, Shibata K, Sagai H, Yoshimura M. Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci. 2000. 20:6302–6308.

18. Badurski J, Jeziernicka E, Naruszewicz K, Racewicz A. Comparative analysis of three treatment regimens for treating gonarthritis with calcitonin, naproxen and flavonoids based on EULAR criteria and visual analogue scale (VAS). Pol Tyg Lek. 1995. 50:37–40.

19. Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y, Hori M, Suda T. Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology. 1996. 137:4685–4690.

20. Shyu JF, Shih C, Tseng CY, Lin CH, Sun DT, Liu HT, Tsung HC, Chen TH, Lu RB. Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities. Bone. 2007. 40:1329–1342.

21. Franchimont P, Bassleer C, Henrotin Y, Gysen P, Bassleer R. Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. J Clin Endocrinol Metab. 1989. 69:259–266.

22. Sondergaard BC, Madsen SH, Segovia-Silvestre T, Paulsen SJ, Christiansen T, Pedersen C, Bay-Jensen AC, Karsdal MA. Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. BMC Musculoskelet Disord. 2010. 11:62.

23. Di Nino DL, Linsenmayer TF. Positive regulation of endochondral cartilage growth by perichondrial and periosteal calcitonin. Endocrinology. 2003. 144:1979–1983.

24. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage. 2008. 16:638–646.

25. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004. 50:2471–2478.

26. Meulenbelt I, Kloppenburg M, Kroon HM, Houwing-Duistermaat JJ, Garnero P, Hellio-Le Graverand MP, DeGroot J, Slagboom PE. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoarthritis Cartilage. 2007. 15:379–385.

27. Bagger YZ, Tankó LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C. Oral salmon calcitonin induced suppression of urinary collogen type II degradation in postmenapausal women: A new potential treatment of osteoarthritis. Bone. 2005. 37:425–430.

28. Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Lau EM, Arnold M, Christiansen C. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage. 2010. 18:150–159.

29. Lotz M. The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am. 1999. 25:269–282.

30. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage. 2009. 17:384–389.